Stockscreener 앱 받기
60.72
6.05%
-3.91
시간 외 거래:
60.72
Rhythm Pharmaceuticals Inc 주식(RYTM)의 최신 뉴스
Rhythm pharmaceuticals outlines Q3 2025 filing for acquired hypothalamic obesity treatment - MSN
Rhythm Pharmaceuticals Inc (RYTM) Q1 2025 Earnings Call Highlights: Strong IMCIVREE Sales and ... - Yahoo
Rhythm Pharmaceuticals Q1 2025 slides: Revenue grows 45% as HO program advances - Investing.com Canada
RHYTHM PHARMACEUTICALS, INC. SEC 10-Q Report - TradingView
Rhythm Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (15 Ratings) - Benzinga
Rhythm Pharmaceuticals (RYTM) Price Target Raised by Needham | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Rhythm Pharmaceuticals misses Q1 2025 EPS estimates - Investing.com
Rhythm Pharmaceuticals' Q1 Net Loss Narrows, Revenue Increases - marketscreener.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
RYTM Misses Q1 Revenue Estimates, Focuses on Future Therapies for Hypothalamic Obesity | RYTM Stock News - GuruFocus
Rhythm Pharmaceuticals Reports Q1 2025 Earnings: EPS of ($0.81) Misses Estimate, Revenue of $37.7 Million Below Expectations - GuruFocus
Earnings Flash (RYTM) Rhythm Pharmaceuticals Posts Q1 Loss $0.81, vs. FactSet Est of $0.73 Loss - marketscreener.com
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - GlobeNewswire
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update - GlobeNewswire Inc.
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Rare Disease Leader Rhythm Pharmaceuticals Lines Up Triple Conference Appearances in Healthcare Circuit - Stock Titan
Mariner LLC Invests $254,000 in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (RYTM) Expected to Announce Earnings on Wednesday - Defense World
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Shares Climb 36% But Its Business Is Yet to Catch Up - simplywall.st
(RYTM) Trading Report - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by LPL Financial LLC - Defense World
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? - MSN
Wells Fargo & Company MN Boosts Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Target Price at $74.92 - Defense World
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - The Manila Times
Rare Disease Pioneer Rhythm Pharmaceuticals Unveils Q1 2025 Earnings Date: Key Updates Coming - Stock Titan
Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? - MSN
Q2 EPS Estimates for RYTM Raised by Needham & Company LLC - Defense World
RYTM FY2027 EPS Estimate Boosted by Needham & Company LLC - Defense World
Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results - markets.businessinsider.com
Wellington Management Group LLP Sells 2,161 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Rhythm Pharmaceuticals (RYTM): Surge in Interest Following Positive Trial Results | ADTX Stock News - GuruFocus
Raymond James Financial Inc. Purchases New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - Defense World
Canaccord maintains Buy on Rhythm Pharma following Ph3 data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid P - GuruFocus
Rhythm Pharmaceuticals EVP Yann Mazabraud sells $1.08 million in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $1.25m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) Surges on Nasdaq Rebound - GuruFocus
Rhythm Pharmaceuticals Stock (RYTM) Erases YTD Losses This Week - AskTraders.com
Rhythm Pharmaceuticals (RYTM) Target Price Raised by BofA Amid Positive Trial Results | RYTM Stock News - GuruFocus
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 11.9% Following Analyst Upgrade - Defense World
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - MSN
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade - MSN
Rhythm’s setmelanotide cuts BMI by 20% - The Pharma Letter
Street View: Blockbuster potential for Rhythm Pharma's rare obesity disorder drug - TradingView
Morgan Stanley Raises Price Target on Rhythm Pharmaceuticals to $77 From $72, Keeps Overweight Rating - marketscreener.com
Canaccord raises Rhythm Pharma stock target to $92, maintains buy - Investing.com
Oppenheimer maintains Rhythm Pharma Outperform rating, $76 target - Investing.com
Rhythm Pharmaceuticals shares rise on raised target to $80 By Investing.com - Investing.com UK
Canaccord raises Rhythm Pharma stock target to $92, maintains buy By Investing.com - Investing.com Canada
Positive Phase 3 Results and Market Potential Boost Rhythm Pharmaceuticals’ Price Target - TipRanks
5.73%
1.07%
자본화:
|
볼륨(24시간):